Literature DB >> 30113984

Topical Deferoxamine Alleviates Skin Injury and Normalizes Atomic Force Microscopy Patterns Following Radiation in a Murine Breast Reconstruction Model.

Alicia E Snider, Jeremy V Lynn, Kevin M Urlaub, Alexis Donneys, Yekaterina Polyatskaya, Noah S Nelson, Russell E Ettinger, Geoffrey C Gurtner1, Mark M Banaszak Holl2, Steven R Buchman.   

Abstract

BACKGROUND: Breast cancer is most commonly managed with a combination of tumor ablation, radiation, and/or chemotherapy. Despite the oncologic benefit of these treatments, the detrimental effect of radiation on surrounding tissue challenges the attainment of ideal breast reconstruction outcomes. The purpose of this study was to determine the ability of topical deferoxamine (DFO) to reduce cutaneous ulceration and collagen disorganization following radiotherapy in a murine model of expander-based breast reconstruction.
METHODS: Female Sprague-Dawley rats (n = 15) were divided into 3 groups: control (expander), XRT (expander + radiation), and DFO (expander + radiation + deferoxamine [DFO]). Expanders were placed in a submusculocutaneous plane in the right upper back and ultimately filled to 15 mL. Radiation was administered via a fractionated dose of 28 Gy. Deferoxamine was delivered topically for 10 days following radiation. After a 20-day recovery period, skin ulceration and dermal type I collagen organization were analyzed.
RESULTS: Compared with control, the XRT group demonstrated a significant increase in skin ulceration (3.7% vs 43.3%, P = 0.00) and collagen fibril disorganization (26.3% vs 81.8%, P = 0.00). Compared with the XRT group, treatment with topical DFO resulted in a significant reduction in ulceration (43.3% vs 7.0%, P = 0.00) and fibril disorganization (81.8% vs 15.3%, P = 0.00). There were no statistical differences between the control and DFO groups in skin ulceration or collagen disorganization.
CONCLUSIONS: This study suggests topical DFO is capable of reducing skin ulceration and type I collagen fibril disorganization following radiotherapy. This novel application of DFO has potential to enhance expander-based breast reconstruction outcomes and improve quality of life for women suffering the devastating effects of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30113984      PMCID: PMC6179919          DOI: 10.1097/SAP.0000000000001592

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  29 in total

Review 1.  Breast reconstruction after surgery for breast cancer.

Authors:  Peter G Cordeiro
Journal:  N Engl J Med       Date:  2008-10-09       Impact factor: 91.245

2.  Deferoxamine modulates cytokines and growth factors to accelerate cutaneous wound healing in diabetic rats.

Authors:  Mahendra Ram; Vishakha Singh; Sanjay Kumawat; Dhirendra Kumar; Madhu C Lingaraju; Thakur Uttam Singh; Anu Rahal; Surendra Kumar Tandan; Dinesh Kumar
Journal:  Eur J Pharmacol       Date:  2015-06-19       Impact factor: 4.432

Review 3.  Pathophysiology of irradiated skin and breast.

Authors:  J O Archambeau; R Pezner; T Wasserman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

4.  A paradigm shift in U.S. Breast reconstruction: increasing implant rates.

Authors:  Claudia R Albornoz; Peter B Bach; Babak J Mehrara; Joseph J Disa; Andrea L Pusic; Colleen M McCarthy; Peter G Cordeiro; Evan Matros
Journal:  Plast Reconstr Surg       Date:  2013-01       Impact factor: 4.730

5.  Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

Authors:  Dominik Duscher; Evgenios Neofytou; Victor W Wong; Zeshaan N Maan; Robert C Rennert; Mohammed Inayathullah; Michael Januszyk; Melanie Rodrigues; Andrey V Malkovskiy; Arnetha J Whitmore; Graham G Walmsley; Michael G Galvez; Alexander J Whittam; Michael Brownlee; Jayakumar Rajadas; Geoffrey C Gurtner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

6.  Up-regulation of vascular endothelial growth factor production by iron chelators.

Authors:  L V Beerepoot; D T Shima; M Kuroki; K T Yeo; E E Voest
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

7.  Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients.

Authors:  Peter G Cordeiro; Andrea L Pusic; Joseph J Disa; Beryl McCormick; Kimberly VanZee
Journal:  Plast Reconstr Surg       Date:  2004-03       Impact factor: 4.730

Review 8.  Breast Reconstruction and Radiation Therapy: An Update.

Authors:  Jonas A Nelson; Joseph J Disa
Journal:  Plast Reconstr Surg       Date:  2017-11       Impact factor: 4.730

9.  Prophylactic amifostine prevents a pathologic vascular response in a murine model of expander-based breast reconstruction.

Authors:  Y Polyatskaya; N S Nelson; J J Rodriguez; A R Zheutlin; S S Deshpande; P A Felice; A Donneys; S R Buchman
Journal:  J Plast Reconstr Aesthet Surg       Date:  2015-10-24       Impact factor: 2.740

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  8 in total

1.  Radiation-Induced Skin Fibrosis: Pathogenesis, Current Treatment Options, and Emerging Therapeutics.

Authors:  Mimi R Borrelli; Abra H Shen; Gordon K Lee; Arash Momeni; Michael T Longaker; Derrick C Wan
Journal:  Ann Plast Surg       Date:  2019-10       Impact factor: 1.539

2.  Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro.

Authors:  Alexandra O Luby; Chitra Subramanian; Lauren K Buchman; Jeremy V Lynn; Kevin M Urlaub; Noah S Nelson; Alexis Donneys; Mark S Cohen; Steven R Buchman
Journal:  Ann Plast Surg       Date:  2020-10       Impact factor: 1.763

3.  A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis.

Authors:  Christopher V Lavin; Darren B Abbas; Evan J Fahy; Daniel K Lee; Michelle Griffin; Nestor M Diaz Deleon; Shamik Mascharak; Kellen Chen; Arash Momeni; Geoffrey C Gurtner; Michael T Longaker; Derrick C Wan
Journal:  J Cell Mol Med       Date:  2021-10-06       Impact factor: 5.310

4.  Transdermal deferoxamine administration improves excisional wound healing in chronically irradiated murine skin.

Authors:  Hendrik Lintel; Darren B Abbas; Christopher V Lavin; Michelle Griffin; Jason L Guo; Nicholas Guardino; Andrew Churukian; Geoffrey C Gurtner; Arash Momeni; Michael T Longaker; Derrick C Wan
Journal:  J Transl Med       Date:  2022-06-17       Impact factor: 8.440

Review 5.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

6.  Deferoxamine to Minimize Fibrosis During Radiation Therapy.

Authors:  Ruth Tevlin; Michael T Longaker; Derrick C Wan
Journal:  Adv Wound Care (New Rochelle)       Date:  2021-07-26       Impact factor: 4.947

7.  Therapeutic Interventions to Reduce Radiation Induced Dermal Injury in a Murine Model of Tissue Expander Based Breast Reconstruction.

Authors:  Alexandra O Luby; Alicia E Snider; Gurjit S Mandair; Kevin M Urlaub; Jeremy V Lynn; Noah S Nelson; Alexis Donneys; Russell E Ettinger; Geoffrey C Gurtner; David Kohn; Steven R Buchman
Journal:  Ann Plast Surg       Date:  2020-11       Impact factor: 1.763

8.  Deferoxamine Treatment Improves Antioxidant Cosmeceutical Formulation Protection against Cutaneous Diesel Engine Exhaust Exposure.

Authors:  Erika Pambianchi; Francesca Ferrara; Alessandra Pecorelli; Mascia Benedusi; Hina Choudhary; Jean-Philippe Therrien; Giuseppe Valacchi
Journal:  Antioxidants (Basel)       Date:  2021-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.